J Cancer 2021; 12(1):38-53. doi:10.7150/jca.49406

Review

Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Vinaya Gogineni1, Susan Morand1, Hannah Staats1, Rachel Royfman1, Monika Devanaboyina1, Katelyn Einloth1, Danielle Dever1, Laura Stanbery2, Phylicia Aaron2, Luisa Manning2, Adam Walter3, Gerald Edelman1, Lance Dworkin1, John Nemunaitis2✉

1. University of Toledo Medical Center, Toledo, OH
2. Gradalis, Inc, Carrollton, TX
3. Promedica Health System, Toledo, OH

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J. Current Ovarian Cancer Maintenance Strategies and Promising New Developments. J Cancer 2021; 12(1):38-53. doi:10.7150/jca.49406. Available from https://www.jcancer.org/v12p0038.htm

File import instruction

Abstract

While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years. Treatment options are less effective at each recurrence highlighting the need for novel maintenance therapies. PolyADP-ribose polymerase (PARP) inhibitors have recently gained approval in ovarian cancer maintenance. Niraparib was approved regardless of BRCA mutation status, however impact on overall survival is limited. Oliparib was approved for BRCA mutant and BRCA wildtype/homologous recombination deficient patients. This review will focus on current frontline ovarian cancer treatment as well molecularly based approaches to ovarian cancer management.

Keywords: ovarian cancer maintenance, HGSOC, ovarian cancer treatment, Vigil